Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RBT-9 is being developed by Renibus Therapeutics as an antiviral agent with organ-protective attributes. With the advent of the coronavirus pandemic, Renibus scientists moved quickly to plan and initiate a clinical trial of RBT-9 in COVID-19 patients.
Lead Product(s): Stannus Protoporphyrin
Therapeutic Area: Infections and Infectious Diseases Product Name: RBT-9
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Renibus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 24, 2020